Molecular Neurodegeneration最新文献

筛选
英文 中文
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands trem2配体相互作用的生物物理图谱揭示了多种阿尔茨海默病配体参与的共享表面
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2025-01-09 DOI: 10.1186/s13024-024-00795-9
Jessica A. Greven, Joshua R. Wydra, Rory A. Greer, Cynthia Zhi, David A. Price, Jordyn D. Svoboda, Christopher L. M. Camitta, Mya Washington, Daisy W. Leung, Yuhua Song, Jen Alexander-Brett, Tom J. Brett
{"title":"Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands","authors":"Jessica A. Greven, Joshua R. Wydra, Rory A. Greer, Cynthia Zhi, David A. Price, Jordyn D. Svoboda, Christopher L. M. Camitta, Mya Washington, Daisy W. Leung, Yuhua Song, Jen Alexander-Brett, Tom J. Brett","doi":"10.1186/s13024-024-00795-9","DOIUrl":"https://doi.org/10.1186/s13024-024-00795-9","url":null,"abstract":"TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer’s disease and other neurodegenerative diseases. While a number of TREM2 ligands have been identified, little is known regarding the structural details of how they engage. To better understand this, we created a protein library of 28 different TREM2 variants that could be used to map interactions with various ligands using biolayer interferometry. The variants are located in previously identified putative binding surfaces on TREM2 called the hydrophobic site, basic site, and site 2. We found that mutations to the hydrophobic site ablated binding to apoE4 and TDP-43. Competition binding experiments indicated that apoE4 and oAβ42 share overlapping binding sites on TREM2. In contrast, binding to C1q was disrupted most strongly by mutations to the basic site, including R46, with some mutations to the hydrophobic site also attenuating binding, thus suggesting a broader mediation of binding across the two sites. Supporting this, competition experiments indicated that C1q binding could be blocked by both apoE and oAβ42. TREM2 binding to IL-34 was mediated by the basic site at a surface centering on R76. Competition binding experiments validated the unique site for IL-34, showing little to no competition with either oAβ42 or apoE4. However, competition experiments between C1q and IL34 suggest that the ligands compete for binding at the basic site. Altogether, our results suggest that TREM2 utilizes the hydrophobic site (consisting of CDR1, CDR2, and CDR3) as a common site to engage multiple ligands, and uses distinct basic sites to engage others. Our findings imply that pharmaceutical strategies targeting these surfaces might be effective to modulate TREM2 functions.","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"27 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142940140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VCP regulates early tau seed amplification via specific cofactors VCP通过特异性辅因子调控早期tau种子扩增
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2025-01-07 DOI: 10.1186/s13024-024-00783-z
Sushobhna Batra, Jaime Vaquer-Alicea, Clarissa Valdez, Skyler P. Taylor, Victor A. Manon, Anthony R. Vega, Omar M. Kashmer, Sourav Kolay, Andrew Lemoff, Nigel J. Cairns, Charles L. White, Marc I. Diamond
{"title":"VCP regulates early tau seed amplification via specific cofactors","authors":"Sushobhna Batra, Jaime Vaquer-Alicea, Clarissa Valdez, Skyler P. Taylor, Victor A. Manon, Anthony R. Vega, Omar M. Kashmer, Sourav Kolay, Andrew Lemoff, Nigel J. Cairns, Charles L. White, Marc I. Diamond","doi":"10.1186/s13024-024-00783-z","DOIUrl":"https://doi.org/10.1186/s13024-024-00783-z","url":null,"abstract":"Neurodegenerative tauopathies may progress based on seeding by pathological tau assemblies, whereby an aggregate is released from one cell, gains entry to an adjacent or connected cell, and serves as a specific template for its own replication in the cytoplasm. Seeding into the complex cytoplasmic milieu happens within hours, implying the existence of unknown factors that regulate this process. We used proximity labeling to identify proteins that control seed amplification within 5 h of seed exposure. We fused split-APEX2 to the C-terminus of tau repeat domain (RD) to reconstitute peroxidase activity 5 h after seeded intracellular tau aggregation. Valosin containing protein (VCP/p97) was the top hit. VCP harbors dominant mutations that underlie two neurodegenerative diseases, multisystem proteinopathy and vacuolar tauopathy, but its mechanistic role is unclear. We used immortalized cells and human neurons to study the effects of VCP on tau seeding. We exposed cells to fibrils or brain homogenates in cell culture media and measured effects on uptake and induction of intracellular tau aggregation following various genetic and pharmacological manipulations of VCP. VCP knockdown reduced tau seeding. Chemical inhibitors had opposing effects on seeding in HEK293T tau biosensor cells and human neurons: ML-240 increased seeding efficiency, whereas NMS-873 decreased it. The inhibitors only functioned when administered within 8 h of seed exposure, indicating a role for VCP early in seed processing. We screened 30 VCP co-factors in HEK293T biosensor cells by genetic knockout or knockdown. Reduction of ATXN3, NSFL1C, UBE4B, NGLY1, and OTUB1 decreased tau seeding, as did NPLOC4, which also uniquely increased soluble tau levels. By contrast, reduction of FAF2 increased tau seeding. Divergent effects on tau seeding of chemical inhibitors and cofactor reduction indicate that VCP regulates this process. This is consistent with a cytoplasmic processing complex centered on VCP that directs seeds acutely towards degradation vs. amplification.","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"98 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142935809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Positron emission tomography tracers for synucleinopathies 突触核蛋白病的正电子发射断层扫描示踪剂
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2025-01-05 DOI: 10.1186/s13024-024-00787-9
Jie Xiang, Zhentao Zhang, Shengxi Wu, Keqiang Ye
{"title":"Positron emission tomography tracers for synucleinopathies","authors":"Jie Xiang, Zhentao Zhang, Shengxi Wu, Keqiang Ye","doi":"10.1186/s13024-024-00787-9","DOIUrl":"https://doi.org/10.1186/s13024-024-00787-9","url":null,"abstract":"Synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, are characterized by the aggregation of α-synuclein. Variations in brain distribution allow for differentiation among these diseases and facilitate precise clinical diagnosis. However, distinguishing between synucleinopathies and Parkinsonism with tauopathies poses a challenge, significantly impacting clinical drug development. Therefore, molecular imaging is crucial for synucleinopathies, particularly for clinical diagnosis, assessment of drug efficacy, and disease surveillance. In recent years, advances in molecular imaging have led to rapid development of α-synuclein-specific tracers for positron emission tomography (PET), most of which are still in pre-clinical stages. Interestingly, some of these tracers share similar compound skeletal structures and are currently undergoing optimization for clinical application. Despite this progress, there remain challenges in developing α-synuclein tracers. This review summarizes recent findings on promising PET tracers and discusses representative compounds’ characteristics while offering suggestions for further research orientation.","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"87 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142929119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinct regulation of Tau Monomer and aggregate uptake and intracellular accumulation in human neurons 人类神经元中Tau单体和聚集体摄取和细胞内积累的独特调控
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2024-12-31 DOI: 10.1186/s13024-024-00786-w
Amir T. Marvian, Tabea Strauss, Qilin Tang, Benjamin J. Tuck, Sophie Keeling, Daniel Rüdiger, Negar Mirzazadeh Dizaji, Hossein Mohammad-Beigi, Brigitte Nuscher, Pijush Chakraborty, Duncan S. Sutherland, William A. McEwan, Thomas Köglsperger, Stefan Zahler, Markus Zweckstetter, Stefan F. Lichtenthaler, Wolfgang Wurst, Sigrid Schwarz, Günter Höglinger
{"title":"Distinct regulation of Tau Monomer and aggregate uptake and intracellular accumulation in human neurons","authors":"Amir T. Marvian, Tabea Strauss, Qilin Tang, Benjamin J. Tuck, Sophie Keeling, Daniel Rüdiger, Negar Mirzazadeh Dizaji, Hossein Mohammad-Beigi, Brigitte Nuscher, Pijush Chakraborty, Duncan S. Sutherland, William A. McEwan, Thomas Köglsperger, Stefan Zahler, Markus Zweckstetter, Stefan F. Lichtenthaler, Wolfgang Wurst, Sigrid Schwarz, Günter Höglinger","doi":"10.1186/s13024-024-00786-w","DOIUrl":"https://doi.org/10.1186/s13024-024-00786-w","url":null,"abstract":"The prion-like spreading of Tau pathology is the leading cause of disease progression in various tauopathies. A critical step in propagating pathologic Tau in the brain is the transport from the extracellular environment and accumulation inside naïve neurons. Current research indicates that human neurons internalize both the physiological extracellular Tau (eTau) monomers and the pathological eTau aggregates. However, similarities or differences in neuronal transport mechanisms between Tau species remain elusive. Monomers, oligomers, and fibrils of recombinant 2N4R Tau were produced and characterized by biochemical and biophysical methods. A neuronal eTau uptake and accumulation assay was developed for human induced pluripotent stem cell-derived neurons (iPSCNs) and Lund human mesencephalic cells (LUHMES)-derived neurons. Mechanisms of uptake and cellular accumulation of eTau species were studied by using small molecule inhibitors of endocytic mechanisms and siRNAs targeting Tau uptake mediators. Extracellular Tau aggregates accumulated more than monomers in human neurons, mainly due to the higher efficiency of small fibrillar and soluble oligomeric aggregates in intraneuronal accumulation. A competition assay revealed a distinction in the neuronal accumulation between physiological eTau Monomers and pathology-relevant aggregates, suggesting differential transport mechanisms. Blocking heparan sulfate proteoglycans (HSPGs) with heparin only inhibited the accumulation of eTau aggregates, whereas monomers’ uptake remained unaltered. At the molecular level, the downregulation of genes involved in HSPG synthesis exclusively blocked neuronal accumulation of eTau aggregates but not monomers, suggesting its role in the transport of pathologic Tau. Moreover, the knockdown of LRP1, as a receptor of Tau, mainly reduced the accumulation of monomeric form, confirming its involvement in Tau’s physiological transport. These data propose that despite the similarity in the cellular mechanism, the uptake and accumulation of eTau Monomers and aggregates in human neurons are regulated by different molecular mediators. Thus, they address the possibility of targeting the pathological spreading of Tau aggregates without disturbing the probable physiological or non-pathogenic transport of Tau Monomers.","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"161 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142905014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion 靶向长读测序以量化C9orf72重复扩增的甲基化
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2024-12-21 DOI: 10.1186/s13024-024-00790-0
Evan Udine, NiCole A. Finch, Mariely DeJesus-Hernandez, Jazmyne L. Jackson, Matthew C. Baker, Siva Arumugam Saravanaperumal, Eric Wieben, Mark T.W. Ebbert, Jaimin Shah, Leonard Petrucelli, Rosa Rademakers, Björn Oskarsson, Marka van Blitterswijk
{"title":"Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion","authors":"Evan Udine, NiCole A. Finch, Mariely DeJesus-Hernandez, Jazmyne L. Jackson, Matthew C. Baker, Siva Arumugam Saravanaperumal, Eric Wieben, Mark T.W. Ebbert, Jaimin Shah, Leonard Petrucelli, Rosa Rademakers, Björn Oskarsson, Marka van Blitterswijk","doi":"10.1186/s13024-024-00790-0","DOIUrl":"https://doi.org/10.1186/s13024-024-00790-0","url":null,"abstract":"The gene C9orf72 harbors a non-coding hexanucleotide repeat expansion known to cause amyotrophic lateral sclerosis and frontotemporal dementia. While previous studies have estimated the length of this repeat expansion in multiple tissues, technological limitations have impeded researchers from exploring additional features, such as methylation levels. We aimed to characterize C9orf72 repeat expansions using a targeted, amplification-free long-read sequencing method. Our primary goal was to determine the presence and subsequent quantification of observed methylation in the C9orf72 repeat expansion. In addition, we measured the repeat length and purity of the expansion. To do this, we sequenced DNA extracted from blood for 27 individuals with an expanded C9orf72 repeat. For these individuals, we obtained a total of 7,765 on-target reads, including 1,612 fully covering the expanded allele. Our in-depth analysis revealed that the expansion itself is methylated, with great variability in total methylation levels observed, as represented by the proportion of methylated CpGs (13 to 66%). Interestingly, we demonstrated that the expanded allele is more highly methylated than the wild-type allele (P-Value = 2.76E-05) and that increased methylation levels are observed in longer repeat expansions (P-Value = 1.18E-04). Furthermore, methylation levels correlate with age at collection (P-Value = 3.25E-04) as well as age at disease onset (P-Value = 0.020). Additionally, we detected repeat lengths up to 4,088 repeats (~ 25 kb) and found that the expansion contains few interruptions in the blood. Taken together, our study demonstrates robust ability to quantify methylation of the expanded C9orf72 repeat, capturing differences between individuals harboring this expansion and revealing clinical associations.","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"64 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142869961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dementia with lewy bodies patients with high tau levels display unique proteome profiles 高tau蛋白水平的路易体痴呆患者表现出独特的蛋白质组谱
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2024-12-19 DOI: 10.1186/s13024-024-00782-0
Sinead Greally, Mukesh Kumar, Christoph Schlaffner, Hanne van der Heijden, Elisabeth S. Lawton, Deeptarup Biswas, Sabina Berretta, Hanno Steen, Judith A. Steen
{"title":"Dementia with lewy bodies patients with high tau levels display unique proteome profiles","authors":"Sinead Greally, Mukesh Kumar, Christoph Schlaffner, Hanne van der Heijden, Elisabeth S. Lawton, Deeptarup Biswas, Sabina Berretta, Hanno Steen, Judith A. Steen","doi":"10.1186/s13024-024-00782-0","DOIUrl":"https://doi.org/10.1186/s13024-024-00782-0","url":null,"abstract":"Clinical studies have long observed that neurodegenerative disorders display a range of symptoms and pathological features and, in some cases, overlap, suggesting that these diseases exist on a spectrum. Dementia with Lewy Bodies (DLB), a synucleinopathy, is a prominent example, where symptomatic similarities with tauopathy, Alzheimer’s disease, are observed. Although tau pathology has been observed in DLB, the interplay between tau and α-synuclein is poorly understood at a molecular level. Quantitative mass spectrometry analysis was used to measure protein abundance in the insoluble fraction from cortical brain tissue from pathologically diagnosed DLB subjects (n = 30) and age-matched controls (n = 29). Using tau abundance, we stratified the DLB subjects into two subgroups termed DLBTau+ (higher abundance) and DLBTau− (lower abundance). We conducted proteomic analysis to characterize and compare the cortical proteome of DLB subjects exhibiting elevated tau, as well as the molecular modifications of tau and α-synuclein to explore the dynamic between tau and α-synuclein pathology in these patients. Proteomic analyses revealed distinct global protein dysregulations in DLBTau+ and DLBTau− subjects when compared to controls. Notably, DLBTau+ patients exhibited increased levels of tau, along with ubiquitin, and APOE, indicative of cortical proteome alterations associated with elevated tau. Comparing DLBTau+ and DLBTau− groups, we observed significant upregulation of cytokine signaling and metabolic pathways in DLBTau− patients, while DLBTau+ subjects showed increases in protein ubiquitination processes and regulation of vesicle-mediated transport. Additionally, we examined the post-translational modification patterns of tau and α-synuclein. Our analysis revealed distinct phosphorylation and ubiquitination sites on α-synuclein between groups. Moreover, we observed increased modifications on tau specifically within the DLBTau+ subgroup. This molecular-level data supports the idea of neurodegenerative disease as a continuum of diseases with distinct PTM profiles DLBTau+ and DLBTau− patients in comparison to AD. These findings further emphasize the importance of identifying specific and tailored therapeutic approaches targeting the involved proteopathies in the neurodegenerative disease spectrum.","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"22 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis 小胶质细胞CD2AP缺乏在阿尔茨海默病淀粉样变模型中发挥保护作用
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2024-12-18 DOI: 10.1186/s13024-024-00789-7
Lingliang Zhang, Lingling Huang, Yuhang Zhou, Jian Meng, Liang Zhang, Yunqiang Zhou, Naizhen Zheng, Tiantian Guo, Shanshan Zhao, Zijie Wang, Yuanhui Huo, Yingjun Zhao, Xiao-fen Chen, Honghua Zheng, David M. Holtzman, Yun-wu Zhang
{"title":"Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis","authors":"Lingliang Zhang, Lingling Huang, Yuhang Zhou, Jian Meng, Liang Zhang, Yunqiang Zhou, Naizhen Zheng, Tiantian Guo, Shanshan Zhao, Zijie Wang, Yuanhui Huo, Yingjun Zhao, Xiao-fen Chen, Honghua Zheng, David M. Holtzman, Yun-wu Zhang","doi":"10.1186/s13024-024-00789-7","DOIUrl":"https://doi.org/10.1186/s13024-024-00789-7","url":null,"abstract":"The CD2-associated protein (CD2AP) was initially identified in peripheral immune cells and regulates cytoskeleton and protein trafficking. Single nucleotide polymorphisms (SNPs) in the CD2AP gene have been associated with Alzheimer’s disease (AD). However, the functional role of CD2AP, especially its role in microglia during AD onset, remains elusive. CD2AP protein levels in cultured primary cells and in 5xFAD mice was studied. Microglial CD2AP-deficient mice were crossed with 5xFAD mice and the offspring were subjected to neuropathological assessment, behavioral tests, electrophysiology, RNA-seq, Golgi staining, and biochemistry analysis. Primary microglia were also isolated for assessing their uptake and morphology changes. We find that CD2AP is abundantly expressed in microglia and its levels are elevated in the brain of AD patients and the 5xFAD model mice at pathological stages. We demonstrate that CD2AP haploinsufficiency in microglia significantly attenuates cognitive and synaptic deficits, weakens the response of microglia to Aβ and the formation of disease-associated microglia (DAM), and alleviates synapse loss in 5xFAD mice. We show that CD2AP-deficient microglia exhibit compromised uptake ability. In addition, we find that CD2AP expression is positively correlated with the expression of the complement C1q that is important for synapse phagocytosis and the formation of DAM in response to Aβ deposition. Moreover, we reveal that CD2AP interacts with colony stimulating factor 1 receptor (CSF1R) and regulates CSF1R cell surface levels, which may further affect C1q expression. Our results demonstrate that CD2AP regulates microgliosis and identify a protective function of microglial CD2AP deficiency against Aβ deposition, suggesting the importance of detailed investigation of AD-associated genes in different brain cells for thoroughly understanding their exact contribution to AD.","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"114 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The UFMylation pathway is impaired in Alzheimer’s disease 阿尔茨海默病的 UFMylation 通路受损
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2024-12-18 DOI: 10.1186/s13024-024-00784-y
Tingxiang Yan, Michael G. Heckman, Emily C. Craver, Chia-Chen Liu, Bailey D. Rawlinson, Xue Wang, Melissa E. Murray, Dennis W. Dickson, Nilufer Ertekin-Taner, Zhenkun Lou, Guojun Bu, Wolfdieter Springer, Fabienne C. Fiesel
{"title":"The UFMylation pathway is impaired in Alzheimer’s disease","authors":"Tingxiang Yan, Michael G. Heckman, Emily C. Craver, Chia-Chen Liu, Bailey D. Rawlinson, Xue Wang, Melissa E. Murray, Dennis W. Dickson, Nilufer Ertekin-Taner, Zhenkun Lou, Guojun Bu, Wolfdieter Springer, Fabienne C. Fiesel","doi":"10.1186/s13024-024-00784-y","DOIUrl":"https://doi.org/10.1186/s13024-024-00784-y","url":null,"abstract":"Alzheimer’s disease (AD) is characterized by the presence of neurofibrillary tangles made of hyperphosphorylated tau and senile plaques composed of beta-amyloid. These pathognomonic deposits have been implicated in the pathogenesis, although the molecular mechanisms and consequences remain undetermined. UFM1 is an important, but understudied ubiquitin-like protein that is covalently attached to substrates. UFMylation has recently been identified as major modifier of tau aggregation upon seeding in experimental models. However, potential alterations of the UFM1 pathway in human AD brain have not been investigated yet. Here we used frontal and temporal cortex samples from individuals with or without AD to measure the protein levels of the UFMylation pathway in human brain. We used multivariable regression analyses followed by Bonferroni correction for multiple testing to analyze associations of the UFMylation pathway with neuropathological characteristics, primary biochemical measurements of tau and additional biochemical markers from the same cases. We further studied associations of the UFMylation cascade with cellular stress pathways using Spearman correlations with bulk RNAseq expression data and functionally validated these interactions using gene-edited neurons that were generated by CRISPR-Cas9. Compared to controls, human AD brain had increased protein levels of UFM1. Our data further indicates that this increase mainly reflects conjugated UFM1 indicating hyperUFMylation in AD. UFMylation was strongly correlated with pathological tau in both AD-affected brain regions. In addition, we found that the levels of conjugated UFM1 were negatively correlated with soluble levels of the deUFMylation enzyme UFSP2. Functional analysis of UFM1 and/or UFSP2 knockout neurons revealed that the DNA damage response as well as the unfolded protein response are perturbed by changes in neuronal UFM1 signaling. There are marked changes in the UFMylation pathway in human AD brain. These changes are significantly associated with pathological tau, supporting the idea that the UFMylation cascade might indeed act as a modifier of tau pathology in human brain. Our study further nominates UFSP2 as an attractive target to reduce the hyperUFMylation observed in AD brain but also underscores the critical need to identify risks and benefits of manipulating the UFMylation pathway as potential therapeutic avenue for AD.","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"12 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mystery of gamma wave stimulation in brain disorders 脑紊乱的伽马波刺激之谜
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2024-12-18 DOI: 10.1186/s13024-024-00785-x
Qianting Deng, Chongyun Wu, Emily Parker, Jing Zhu, Timon Cheng-Yi Liu, Rui Duan, Luodan Yang
{"title":"Mystery of gamma wave stimulation in brain disorders","authors":"Qianting Deng, Chongyun Wu, Emily Parker, Jing Zhu, Timon Cheng-Yi Liu, Rui Duan, Luodan Yang","doi":"10.1186/s13024-024-00785-x","DOIUrl":"https://doi.org/10.1186/s13024-024-00785-x","url":null,"abstract":"Neuronal oscillations refer to rhythmic and periodic fluctuations of electrical activity in the central nervous system that arise from the cellular properties of diverse neuronal populations and their interactions. Specifically, gamma oscillations play a crucial role in governing the connectivity between distinct brain regions, which are essential in perception, motor control, memory, and emotions. In this context, we recapitulate various current stimulation methods to induce gamma entrainment. These methods include sensory stimulation, optogenetic modulation, photobiomodulation, and transcranial electrical or magnetic stimulation. Simultaneously, we explore the association between abnormal gamma oscillations and central nervous system disorders such as Alzheimer’s disease, Parkinson’s disease, stroke, schizophrenia, and autism spectrum disorders. Evidence suggests that gamma entrainment-inducing stimulation methods offer notable neuroprotection, although somewhat controversial. This review comprehensively discusses the functional role of gamma oscillations in higher-order brain activities from both physiological and pathological perspectives, emphasizing gamma entrainment as a potential therapeutic approach for neuropsychiatric disorders. Additionally, we discuss future opportunities and challenges in implementing such strategies.","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"64 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons 纠正:帕金森病风险基因组织蛋白酶B促进多巴胺能神经元纤维状α -突触核蛋白清除、溶酶体功能和糖脑苷酶活性
IF 15.1 1区 医学
Molecular Neurodegeneration Pub Date : 2024-12-18 DOI: 10.1186/s13024-024-00791-z
Jace Jones-Tabah, Kathy He, Nathan Karpilovsky, Konstantin Senkevich, Ghislaine Deyab, Isabella Pietrantonio, Thomas Goiran, Yuting Cousineau, Daria Nikanorova, Taylor Goldsmith, Esther del Cid Pellitero, Carol X.-Q. Chen, Wen Luo, Zhipeng You, Narges Abdian, Jamil Ahmad, Jennifer A. Ruskey, Farnaz Asayesh, Dan Spiegelman, Stanley Fahn, Cheryl Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupré, Irina Miliukhina, Alla Timofeeva, Anton Emelyanov, Sofya Pchelina, Lior Greenbaum, Sharon Hassin-Baer, Roy N. Alcalay, Austen Milnerwood, Thomas M. Durcan, Ziv Gan-Or, Edward A. Fon
{"title":"Correction: The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons","authors":"Jace Jones-Tabah, Kathy He, Nathan Karpilovsky, Konstantin Senkevich, Ghislaine Deyab, Isabella Pietrantonio, Thomas Goiran, Yuting Cousineau, Daria Nikanorova, Taylor Goldsmith, Esther del Cid Pellitero, Carol X.-Q. Chen, Wen Luo, Zhipeng You, Narges Abdian, Jamil Ahmad, Jennifer A. Ruskey, Farnaz Asayesh, Dan Spiegelman, Stanley Fahn, Cheryl Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupré, Irina Miliukhina, Alla Timofeeva, Anton Emelyanov, Sofya Pchelina, Lior Greenbaum, Sharon Hassin-Baer, Roy N. Alcalay, Austen Milnerwood, Thomas M. Durcan, Ziv Gan-Or, Edward A. Fon","doi":"10.1186/s13024-024-00791-z","DOIUrl":"https://doi.org/10.1186/s13024-024-00791-z","url":null,"abstract":"<p><b>Correction</b><b>: </b><b>Mol Neurodegeneration 19, 88 (2024)</b></p><p><b>https://doi.org/10.1186/s13024-024-00779-9</b></p><br/><p>The authors wish to note the Grant ID, MFFF – 007905 relating to the mentioned grants to ZGO and EAF from the Michael J. Fox Foundation which was mistakenly omitted from the original article [1].</p><p>The authors also wish to note that Lior Greenbaum is only affiliated to affiliation #14 (Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel).</p><ol data-track-component=\"outbound reference\" data-track-context=\"references section\"><li data-counter=\"1.\"><p>Jones-Tabah J, He K, Karpilovsky N, et al. The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons. Mol Neurodegeneration. 2024;19:88. https://doi.org/10.1186/s13024-024-00779-9.</p><p>Article CAS Google Scholar </p></li></ol><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, McGill Parkinson Program, Montreal Neurological Institute-Hospital, McGill University, Montreal, Québec, Canada</p><p>Jace Jones-Tabah, Kathy He, Nathan Karpilovsky, Konstantin Senkevich, Ghislaine Deyab, Isabella Pietrantonio, Thomas Goiran, Esther del Cid Pellitero, Jamil Ahmad, Jennifer A. Ruskey, Farnaz Asayesh, Dan Spiegelman, Ziv Gan-Or & Edward A. Fon</p></li><li><p>Department of Neurology and Neurosurgery, McGill University, Montréal, Canada</p><p>Jace Jones-Tabah, Konstantin Senkevich, Yuting Cousineau, Jamil Ahmad, Jennifer A. Ruskey, Oury Monchi, Austen Milnerwood & Edward A. Fon</p></li><li><p>Early Drug Discovery Unit (EDDU), Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada</p><p>Taylor Goldsmith, Carol X.-Q. Chen, Wen Luo, Zhipeng You, Narges Abdian & Thomas M. Durcan</p></li><li><p>Research Department, Bioinformatics Institute, Saint-Petersburg, Russia</p><p>Daria Nikanorova</p></li><li><p>Department of Human Genetics, McGill University, Montréal, Canada</p><p>Farnaz Asayesh & Ziv Gan-Or</p></li><li><p>Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA</p><p>Stanley Fahn, Cheryl Waters & Roy N. Alcalay</p></li><li><p>Département de Radiologie, Radio-Oncologie Et Médecine Nucléaire, Université de Montréal, Montréal, QC, Canada</p><p>Oury Monchi</p></li><li><p>Centre de Recherche de L’Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada</p><p>Oury Monchi</p></li><li><p>Sleep Unit, Department of Neurology, National Reference Center for Narcolepsy, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France</p><p>Yves Dauvilliers<","PeriodicalId":18800,"journal":{"name":"Molecular Neurodegeneration","volume":"11 1","pages":""},"PeriodicalIF":15.1,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信